Drug Profile
GL 1001
Alternative Names: GL1001; ORE 1001Latest Information Update: 25 Sep 2015
Price :
$50
*
At a glance
- Originator Millennium Pharmaceuticals
- Developer Ore Pharmaceuticals
- Class Anti-inflammatories; Small molecules
- Mechanism of Action ACE inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
- Available For Licensing Yes
Highest Development Phases
- Discontinued Inflammatory bowel diseases; NSAID-induced ulcer; Obesity; Ulcerative colitis
Most Recent Events
- 10 Sep 2009 Pharmacodynamics data from a preclinical trial in Inflammatory bowel disease released by Ore Pharmaceuticals
- 06 Dec 2008 Adverse events data from a phase I trial in Inflammatory disease released by Ore Pharmaceuticals
- 06 Dec 2008 Ore Pharmaceuticals completes phase I trial in Inflammatory disease